patients with Multiple Sclerosis MedDRA version: 14.1 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: SOC Classification code 10014698 Term: Endocrine disorders System Organ Class: 10014698 - Endocrine disorders
Conditions
Interventions
Pharmaceutical Form: Powder and solvent for solution for infusion
INN or Proposed INN: Somatorelin
Concentration unit: µg microgram(s)
Concentration number: 50-
Sponsors
UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 30-50 yrs with Multiple sclerosis and never treated Written informed consent to participate into the study. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: No exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the prevalence of GHD and/ or IGF-I deficiency in patients with multiple sclerosis;Secondary Objective: Correlate the prevalence of GH and/or IGF-I deficit with the Index of disability and the Multiple Sclerosis Severity Score;Primary end point(s): To investigate the prevalence of GHD and/ or IGF-I deficiency in patients with multiple sclerosis | — |
Countries
Italy
Outcome results
None listed